News for Porton Pharma Solutions Ltd. (300363.SZ)

CHONGQING, China, Dec. 23, 2024 /PRNewswire/ -- On December 20, 2024, Porton Pharma Solutions (hereinafter referred to as 'company' or 'Porton') and Dragon Sail Pharmaceutical (Shanghai) Co., Ltd. (a subsidiary of Guilin Sanjin, hereinafter referred to as 'Dragon Sail Pharmaceutical') formally signed a strategic cooperation agreement in Guilin, southern of China. This collaboration aims to carry out in-depth cooperation in the research, development, production, and supply chain integration of antibody-drug conjugates (ADC). Attendees at the signing ceremony included Mr. Ju Nianfeng, Chairman and General Manager of Porton Pharma Solutions, Mr. Zou Xun, Chairman of Guilin Sanjin, and Mr. Tan Kai, General Manager of Dragon Sail Pharmaceutical.

CHONGQING, China, Dec. 12, 2024 /PRNewswire/ -- Recently, Porton Pharma Solutions Ltd. ('Porton') announced a strategic partnership with Aojin Life Sciences (Yixing) Co., Ltd. ('Aojin Life Sciences').

SUZHOU, China, July 30, 2024 /PRNewswire/ -- On July 29, 2024, Porton Advanced Solutions ('Porton Advanced') announced that it had reached a strategic cooperation with Guangzhou Geneseed Biotech Co., Ltd ('Geneseed Biotech'). Both sides will combine their respective strengths in the field of gene therapy to jointly provide better drug development services. Leveraging Porton Advanced's end-to-end cell and gene therapy CDMO service platform and resource advantages, combined with Geneseed Biotech's comprehensive core patented technologies in circRNA drug concept validation and process development, the two companies will jointly propel technological innovation and clinical translation, thereby accelerating the implementation of innovative circRNA therapies.

CHONGQING, China, July 8, 2024 /PRNewswire/ -- Porton J-STAR today announced that Enabling Technologies Consortium (ETC) has awarded a two-year contract to J-STAR to collaborate on 'Co-processing Platform Technology.'

SUZHOU, China, June 25, 2024 /PRNewswire/ -- Porton Advanced recently introduced the MaxCyte cGMP-grade ExPERT GTx Flow Electroporation instrument to its cell therapy platform, marking the company as the first cell therapy CDMO in China to possess this clinical-grade flow electroporation system. This equipment, known for its exceptional high transfection efficiency and cell viability, is capable of handling flexible transfection volumes and covering the entire process from research to clinical stages and cGMP production. It also seamlessly scales up for large-volume preparations. MaxCyte has already successfully supported the market launch of the world's first CRISPR/CAS9 gene-edited therapeutic, Casgevy.

Pharmaceutical chemicals could be manufactured in a more sustainable and environmentally friendly way, increasing demand in coming years....

Increasing demand for enzyme-based products in the treatment of cancer, cardiovascular disease, and lysosomal diseases is expected to drive the growth of...

/PRNewswire/ -- On February 20, 2023, Porton Advanced Solutions Ltd. (Porton Advanced) and Yinjia (Shanghai) Biosciences Co., Ltd. (Yinjia Biosciences)...

/PRNewswire/ -- On August 20, 2022, Porton Advanced Solutions (hereinafter referred to as "Porton Advanced") and Kun Tuo Medical Research and Development...